Literature DB >> 29972332

The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials.

Wuwan Wang1, Xiankang Hu2, Weitin Liao2, W H Rutahoile1, David J Malenka3, Xiaofang Zeng1, Yunjing Yang1, Panpan Feng1, Li Wen1, Wei Huang1.   

Abstract

No previous meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor. We aimed to evaluate the efficacy and safety of pulmonary vasodilators in Fontan patients. Relevant studies were identified by searching the PubMed, Embase, and Cochrane Library databases. Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant improvement (mean difference = -0.39, 95% CI: [-0.72, -0.05]) in the New York Heart Association (NYHA) functional class. The 6-minute walking distance (6MWD) was significantly increased by 134 m (95% CI: [86.07, 181.94]), and the peak VO2 was also significantly improved (mean difference = 1.42 ml·(kg·min)-1, 95% CI: [0.21, 2.63]). Additionally, the mean pulmonary artery pressure (mPAP) was significantly reduced (mean difference = -2.25 mmHg, 95% CI: [-3.00, -1.50]). No significant change was found in mortality or in brain natriuretic peptide (BNP) or N-terminal pronatriuretic peptide (NT-proBNP). Four studies reported no side effects and good drug tolerance, and two studies reported mild adverse effects. The present meta-analysis indicated that pulmonary vasodilators (primarily the PDE-5 inhibitor and endothelin-1 receptor antagonist) significantly improved the hemodynamics of Fontan patients, reduced the NYHA functional class and increased the 6MWD. The peak oxygen consumption was also improved. No significant change was observed in mortality or in the BNP or NT-proBNP level. Overall, the pulmonary vasodilators were well tolerated. This finding needs to be confirmed in future studies.

Entities:  

Keywords:  Fontan procedure; PDE-5 inhibitor; endothelin-1 receptor antagonist; outcomes

Year:  2018        PMID: 29972332      PMCID: PMC6348526          DOI: 10.1177/2045894018790450

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  5 in total

Review 1.  Pulmonary vasodilator therapy after the Fontan procedure: a meta-analysis.

Authors:  Dongxu Li; Xu Zhou; Qi An; Yuan Feng
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

Review 2.  Invasive Hemodynamic Evaluation of the Fontan Circulation: Current Day Practice and Limitations.

Authors:  Ashish H Shah; Shakeel A Qureshi; Richard A Krasuski
Journal:  Curr Cardiol Rep       Date:  2022-03-01       Impact factor: 2.931

3.  Use of pulmonary vasodilators in Fontan patients: a useful strategy to improve functional status and delay transplantation?

Authors:  Astrid E Lammers; Tilman Humpl
Journal:  Pulm Circ       Date:  2018-08-20       Impact factor: 3.017

4.  Pulmonary vasodilator therapy as treatment for patients with a Fontan circulation: the Emperor's new clothes?

Authors:  Floris-Jan S Ridderbos; Quint A J Hagdorn; Rolf M F Berger
Journal:  Pulm Circ       Date:  2018-10-19       Impact factor: 3.017

5.  Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.

Authors:  Pascal Amedro; Arthur Gavotto; Hamouda Abassi; Marie-Christine Picot; Stefan Matecki; Sophie Malekzadeh-Milani; Marilyne Levy; Magalie Ladouceur; Caroline Ovaert; Philippe Aldebert; Jean-Benoit Thambo; Alain Fraisse; Marc Humbert; Sarah Cohen; Alban-Elouen Baruteau; Clement Karsenty; Damien Bonnet; Sebastien Hascoet
Journal:  ESC Heart Fail       Date:  2020-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.